Bioequivalence Study of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Amoxicillin and Clavulanic Acid 500 mg/125 mg film-coated tablets in healthy participants under fed conditions. Bioequivalence studies are crucial in determining whether a generic product releases its active ingredients into the bloodstream at the same rate and extent as the original branded product. This is clinically relevant as it ensures therapeutic equivalence, allowing healthcare providers to confidently prescribe generic versions of medications, ensuring patient safety and treatment efficacy.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants do not have any specific medical conditions as a prerequisite for inclusion in the trial. Information regarding lifestyle considerations such as diet, physical activity, or habits has not been provided. The sponsor has not specified any key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioequivalence** of Amoxicillin and Clavulanic Acid 500 mg/125 mg film-coated tablets in healthy participants under fed conditions. This trial is a Phase 2 study, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is July 5, 2024, with an anticipated end date of August 24, 2024. The trial does not involve participants with any specific medical condition, as it is conducted in healthy individuals.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the test or reference product under controlled conditions. The trial will include multiple follow-up visits to monitor the participants' health and collect necessary data to assess the primary and secondary endpoints. The end-of-study visit will conclude the trial, where final assessments and data collection will occur.

The expected length of participant involvement is approximately two months, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. Consequently, no further information can be offered regarding the substances used in this study.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on July 5, 2024, with an estimated end date of August 24, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 2 study, which generally aims to evaluate the effectiveness of a treatment in a specific patient population. The trial's design and execution will adhere to rigorous clinical standards to ensure the reliability and validity of the efficacy data collected.